Christopher Yea, CHIEF DEVELOPMENT OFFICER at KalVista Pharmaceuticals, Inc. (KALV), sold 2,362 shares at $13.22 ($31K) on 2025-08-22, disclosed to the SEC on 2025-08-25.
Seasonal sale ($31k) by CHIEF DEVELOPMENT OFFICER — this insider has traded KALV in August in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| KALV | SELL | 2026-05-26 | $63K | — | Filing → |
| KALV | SELL | 2026-05-19 | $30K | — | Filing → |
| KALV | SELL | 2026-02-24 | $68K | — | Filing → |